A monoclonal antibody demonstrating specificity for drug-resistance cells
Immunology Letters
|July 1, 1982
Abstract:
We have described a monoclonal antibody with specificity for permeability-altered drug-resistant cells. This gamma G2b antibody was characterized by antibody-mediated complement-dependent cytotoxicity and by immunofluorescence analysis using a flow cytometer-cell sorter. Further experiments with the flow cytometer showed that vinblastine=resistant cells exposed to that drug had a wider range of fluorescence intensity and had a modal channel 4 times as bright as the same cells cultured in growth medium. We believe that this monoclonal antibody recognizes part of the "P' glycoprotein found on drug-resistant Chinese hamster ovary cells.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...